TABLE 6.
HR (95% CI) | P | |
---|---|---|
Biochemical failure (n = 260)* | ||
Increasing iPSA | 1.018 (1.015-1.022) | <.0001 |
Gleason score ≥7 | 1.958 (1.491-2.570) | <.0001 |
Increasing RT dose | 0.919 (0.885-0.955) | <.0001 |
T3 | 2.130 (1.419-3.199) | .0003 |
Distant metastasis (n = 50)* | ||
Gleason score ≥7 | 3.205 (1.782-5.767) | .0001 |
T3 | 5.657 (2.918-10.969) | <.0001 |
nPSA12 >2 ng/mL | 3.400 (1.930-5.988) | <.0001 |
Increasing RT dose | 0.904 (0.827-0.988) | .0262 |
Cause-specific mortality (n = 17)* | ||
nPSA12 >2 ng/mL | 3.881 (1.429-10.536) | .0078 |
T3 | 4.037 (1.312-12.428) | .0150 |
Overall mortality (n = 126)* | ||
Gleason score ≥7 | 1.657 (1.113-2.466) | .0129 |
Increasing RT dose | 0.913 (0.863-0.967) | .0019 |
Age | 1.059 (1.030-1.089) | <.0001 |
HR indicates hazard ratio; CI, 95% confidence interval; iPSA, initial PSA; RT Dose, radiotherapy dose in Gy; nPSA12, nadir PSA within 12 months.
Number of events for each endpoint in parentheses.